New treatment modalities--the urologist's view.

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Metastatic renal cell carcinoma (mRCC) treatment remains a significant clinical challenge.
• Current therapies, including biochemotherapy, offer limited response rates and require careful patient selection.
• Identifying prognostic factors is essential for optimizing treatment strategies in mRCC.

Purpose of the Study:

• To evaluate the efficacy of biochemotherapy for metastatic renal cell carcinoma.
• To identify patient subgroups that benefit most from biochemotherapy.
• To discuss the role of nephrectomy in conjunction with systemic therapy for mRCC.

Main Methods:

• Biochemotherapy regimen including interleukin-2 (IL-2) s.c., interferon-alpha2 (IFN-a2) s.c., and 5-fluorouracil (5-FU) i.v.
• Assessment of risk parameters: BSR, LDH, neutrophilic granulocytes, hemoglobin, and metastasis location.
• Analysis of response rates and survival in relation to risk factors and treatment modalities.

Main Results:

• Biochemotherapy achieves response rates of 30-40% in unselected mRCC patients.
• Low-risk patients (absence of specific adverse parameters) demonstrate significantly better outcomes, with response rates up to 60% and 2-year survival of 65%.
• Patients with adverse risk parameters do not benefit from biochemotherapy; nephrectomy is indicated for symptomatic patients or after response in asymptomatic patients.

Conclusions:

• Biochemotherapy is a viable, tolerable treatment for metastatic RCC, particularly in carefully selected low-risk patients.
• Prognostic risk factors are critical for patient selection to maximize treatment benefits.
• Further research into novel therapies like gene manipulation and anti-angiogenesis is warranted, pending clinical trial results.